Hutchmed completes Saffron trial enrolment, results due 2026
(Alliance News) - Hutchmed China Ltd on Wednesday said patient enrolment has been completed for its phase 3 Saffron trial evaluating the combination of Orpathys and Tagrisso in certain lung cancer patients, with topline results expected in the first half of 2026. Read More